📊

Executive Summary

Preclinical TransCon anti-VEGF prodrug (EYC-0305) developed with Eyconis for extended-duration treatment of wet AMD, DME, and other retinal vascular diseases

TransCon_aVEGF_EYC-0305

· TransCon prodrug

Preclinical

Target:

Mechanism of Action

Target Biology

No target biology data available.

Clinical Data

No clinical trial data available.

Market Opportunity

Partner

Eyconis

Catalysts & Upcoming Events

No catalyst data available.

Data sourced exclusively from public filings, corporate presentations, and published clinical data. For informational purposes only. Not investment advice. Satya Bio does not provide recommendations to buy or sell securities. Terms · Privacy